Skip to main content

Genzyme Molecular Oncology Will Access Dana-Farber Technology


FRAMINGHAM, Mass.--Genzyme Molecular Oncology announced that it has entered into an agreement with the Dana-Farber Cancer Institute that will give the company an option to exclusively license novel fusion cell technology developed by researchers at Dana-Farber. Genzyme Molecular also said it has initiated funding at the institute.

Genzyme Molecular plans to combine fusion cell technology--the subject of a study published last month in the Proceedings of the National Academy of Sciences--with proprietary technologies such as Serial Analysis of Gene Expres sion, and Solid Phase Epitope Recovery, in an integrated antigen discovery program. Genzyme Molecular develops gene-based approaches to cancer therapy and diagnosis and employs an integrated approach to translate information gained through its genomics capabilities into gene therapy, small molecule therapeutics, and genetic diagnostics. Genzyme Molecular Oncology is a division of biotechnology company Genzyme and has its own common stock, not yet publicly traded.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.